Literature DB >> 26982053

IBD and Environment: Are There Differences between East and West.

Richard B Gearry1.   

Abstract

BACKGROUND: The inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC) occur worldwide with differences in epidemiology, etiology and phenotype between regions. Breakthroughs have occurred in IBD genetics, although the genes that predispose to IBD differ between racial groups. What do we know about the 'envirotype' of those who develop IBD, and are there differences between the East and the West? KEY MESSAGES: The strongest IBD risk factor identified to date is a family history of IBD. Whilst likely representing an underlying genetic predisposition, it may also reflect shared environmental factors amongst family members. Cigarette smoking increases the risk of developing CD, whilst smoking is less common in those who develop UC. Having ceased smoking increases the risk of developing UC subsequently. Unlike the West, cigarette smoking appears to play a lesser role in the East. Other environmental risk factors are inconsistent. Studies of migrant populations moving from regions of low to high IBD incidence point to early life as a key time for environmental triggers. In these populations, it is the second generation (those born in the high incidence region) with higher IBD incidence rates than their parents. Early life environmental exposures have been studied exhaustively but, except for having been breastfed, few putative early childhood environmental risk factors have been shown consistently to alter the risk of developing IBD.
CONCLUSIONS: The identification of IBD environmental risk factors remains elusive in both the East and West. In the West, case-control studies are unlikely to move the field forward without multi-level (phenotype, genotype, diet history, 'envirotype' and microbiome) data, ideally collected prospectively. Cohort studies (such as the Genes, Environment, Microbiome project) may address some of these issues. However, in the East where IBD incidence is still increasing, well-designed comprehensive case-control studies may identify differences that give an insight into the 'envirotype' driving IBD incidence.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26982053     DOI: 10.1159/000442933

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  10 in total

Review 1.  Environmental triggers in IBD: a review of progress and evidence.

Authors:  Ashwin N Ananthakrishnan; Charles N Bernstein; Dimitrios Iliopoulos; Andrew Macpherson; Markus F Neurath; Raja A Raja Ali; Stephan R Vavricka; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

Review 2.  Determinants of IBD Heritability: Genes, Bugs, and More.

Authors:  Williams Turpin; Ashleigh Goethel; Larbi Bedrani; Kenneth Croitoru Mdcm
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

3.  Protective effect of Lagerstroemia speciosa against dextran sulfate sodium induced ulcerative colitis in C57BL/6 mice.

Authors:  Ghanshyam Chaudhary; Umesh B Mahajan; Sameer N Goyal; Shreesh Ojha; Chandragouda R Patil; Sandeep B Subramanya
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 4.  The role of diet in the prevention and treatment of Inflammatory Bowel Diseases.

Authors:  Rosa Reddavide; Ornella Rotolo; Maria Gabriella Caruso; Elisa Stasi; Maria Notarnicola; Chiara Miraglia; Antonio Nouvenne; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario; Gioacchino Leandro
Journal:  Acta Biomed       Date:  2018-12-17

5.  Bovine Lactoferrin Protects Dextran Sulfate Sodium Salt Mice Against Inflammation and Impairment of Colonic Epithelial Barrier by Regulating Gut Microbial Structure and Metabolites.

Authors:  Shalong Wang; Jingyu Zhou; Da Xiao; Guoshun Shu; Li Gu
Journal:  Front Nutr       Date:  2021-04-16

Review 6.  Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering.

Authors:  Jayshree Mishra; Madyson Stubbs; Longxiang Kuang; Nitza Vara; Priyam Kumar; Narendra Kumar
Journal:  Mediators Inflamm       Date:  2022-01-17       Impact factor: 4.711

7.  Identification of lncRNA DLEU2 as a potential diagnostic biomarker and anti-inflammatory target for ulcerative colitis.

Authors:  Qiuling Lin; Dingguo Zhang; Jian Zhang; Weixiang Luo; Zhenglei Xu; Jun Yao; Lisheng Wang
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

Review 8.  Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.

Authors:  Taku Kobayashi; Tadakazu Hisamatsu; Yasuo Suzuki; Haruhiko Ogata; Akira Andoh; Toshimitsu Araki; Ryota Hokari; Hideki Iijima; Hiroki Ikeuchi; Yoh Ishiguro; Shingo Kato; Reiko Kunisaki; Takayuki Matsumoto; Satoshi Motoya; Masakazu Nagahori; Shiro Nakamura; Hiroshi Nakase; Tomoyuki Tsujikawa; Makoto Sasaki; Kaoru Yokoyama; Naoki Yoshimura; Kenji Watanabe; Miiko Katafuchi; Mamoru Watanabe; Toshifumi Hibi
Journal:  Intest Res       Date:  2018-04-30

Review 9.  Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention.

Authors:  Krasimira Aleksandrova; Beatriz Romero-Mosquera; Vicent Hernandez
Journal:  Nutrients       Date:  2017-08-30       Impact factor: 5.717

10.  Disruption of GPR35 Exacerbates Dextran Sulfate Sodium-Induced Colitis in Mice.

Authors:  Shukkur M Farooq; Yuning Hou; Hainan Li; Megan O'Meara; Yihan Wang; Chunying Li; Jie-Mei Wang
Journal:  Dig Dis Sci       Date:  2018-07-24       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.